Advertisement
Canada markets close in 1 hour 53 minutes
  • S&P/TSX

    22,043.16
    +171.20 (+0.78%)
     
  • S&P 500

    5,075.72
    +65.12 (+1.30%)
     
  • DOW

    38,510.11
    +270.13 (+0.71%)
     
  • CAD/USD

    0.7321
    +0.0020 (+0.28%)
     
  • CRUDE OIL

    83.24
    +1.34 (+1.64%)
     
  • Bitcoin CAD

    91,286.27
    +347.05 (+0.38%)
     
  • CMC Crypto 200

    1,437.41
    +22.65 (+1.60%)
     
  • GOLD FUTURES

    2,340.20
    -6.20 (-0.26%)
     
  • RUSSELL 2000

    2,008.35
    +40.88 (+2.08%)
     
  • 10-Yr Bond

    4.5900
    -0.0330 (-0.71%)
     
  • NASDAQ

    15,723.46
    +272.15 (+1.76%)
     
  • VOLATILITY

    15.99
    -0.95 (-5.61%)
     
  • FTSE

    8,044.81
    +20.94 (+0.26%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • CAD/EUR

    0.6835
    -0.0015 (-0.22%)
     

Sage Therapeutics’ NMDA Receptor–Based Products

Sage Therapeutics’ NMDA Receptor–Based Products

Sage Therapeutics (SAGE) is focused on the development of the products for the treatment of life-threatening central nervous system (or CNS) disorders. One of the products under development, SAGE-718, is based on its NMDA Receptor program.